Dr. Sartor on Sequencing Therapies in Prostate Cancer

Video

In Partnership With:

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Sartor admits oncologists are not entirely sure what the proper sequencing of therapies is, due to a lack of data. However, the identification of biomarkers in prostate cancer is evolving. For oncologists to have a clearer idea of patient selection for specific therapies, they need to first understand the biology of the tumor, he adds.

Studies from Johns Hopkins and Memorial Sloan Kettering Cancer Center show specific biomarkers in patients and what agents they may have resistance to, as well as tumor morphology, Sartor explains.

It appears that certain genes, such as BRCA, may be mutated to a greater extent in prostate cancer than originally by researchers, and could potentially be targetable. If this is the case, PARP inhibitors could be oriented toward that subset of patients.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD